Drug intelligence / Profile preview

isothifluoridine

Development stage: Unknown
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Oral

Overview

Isothifluoridine is a small molecule anti-HBV (Hepatitis B Virus) agent developed by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. Chemically, it is 1-(2-isothiocyanatoethyl)-5-fluorouracil, a non-nucleoside derivative of 5-fluorouracil. It functions as an inhibitor of the HBV DNA polymerase, an essential enzyme for viral replication. By targeting the polymerase, isothifluoridine suppresses the synthesis of viral DNA, offering a potential therapeutic approach for chronic hepatitis B infection. The drug has been evaluated in Phase 1 clinical trials in China (e.g., CTR20130066) to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers.

Other names: isothifluridine异硫氟定

Targets

HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on isothifluoridine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isothifluoridine.

Explore the full profile